LEADER 01654oam 2200517I 450 001 9910711706103321 005 20190204103744.0 035 $a(CKB)5470000002487015 035 $a(OCoLC)885146075 035 $a(OCoLC)995470000002487015 035 $a(EXLCZ)995470000002487015 100 $a20140802d1963 ua 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe solubility of selected elements in liquid plutonium$hII$iTantalum /$fby D.F. Bowersox 210 1$aLos Alamos, New Mexico :$cLos Alamos Scientific Laboratory of the University of California,$d1963. 215 $a1 online resource (10 pages) $cillustrations 225 1 $aTID ;$v4500, 21st ed 300 $a"LAMS-2952." 300 $a"Report written: July 18, 1963." 300 $a"Report distributed: September 27, 1963." 320 $aIncludes bibliographical references (page 11). 606 $aTantalum$xSolubility 606 $aPlutonium 606 $aFission products$xSolubility 606 $aPlutonium$2fast 615 0$aTantalum$xSolubility. 615 0$aPlutonium. 615 0$aFission products$xSolubility. 615 7$aPlutonium. 700 $aBowersox$b D. F.$01403296 712 02$aLos Alamos Scientific Laboratory, 712 02$aU.S. Atomic Energy Commission. 801 0$bOCLCE 801 1$bOCLCE 801 2$bOCLCQ 801 2$bOCLCA 801 2$bOCLCF 801 2$bGPO 906 $aBOOK 912 $a9910711706103321 996 $aThe solubility of selected elements in liquid plutonium$93534526 997 $aUNINA LEADER 03013nam 2200589 450 001 9910822235003321 005 20230803220902.0 010 $a0-19-938964-0 010 $a0-19-938949-7 035 $a(CKB)2550000001194010 035 $a(EBL)1602517 035 $a(SSID)ssj0001112581 035 $a(PQKBManifestationID)12487589 035 $a(PQKBTitleCode)TC0001112581 035 $a(PQKBWorkID)11161386 035 $a(PQKB)11733957 035 $a(MiAaPQ)EBC1602517 035 $a(Au-PeEL)EBL1602517 035 $a(CaPaEBR)ebr10829046 035 $a(CaONFJC)MIL568535 035 $a(OCoLC)869096217 035 $a(EXLCZ)992550000001194010 100 $a20140205h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aLupus $ethe essential clinician's guide /$fDaniel J. Wallace 205 $aSecond edition. 210 1$aNew York :$cOxford University Press,$d2014. 210 4$dİ2014 215 $a1 online resource (130 p.) 225 0$aOxford American rheumatology library 300 $aDescription based upon print version of record. 311 $a0-19-936196-7 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover; Lupus The Essential Clinician's Guide; Copyright; Contents; Chapter 1 The History of Lupus; Chapter 2 Definitions and Classification; Chapter 3 Epidemiology of Systemic Lupus Erythematosus; Chapter 4 Pathogenesis; Chapter 5 Clinical Symptoms and Signs; Chapter 6 Laboratory and Imaging Abnormalities; Chapter 7 Differential Diagnosis and Disease Associations; Chapter 8 Important Subsets and Special Considerations; Chapter 9 Methods of Clinical Ascertainment; Chapter 10 General Treatment Concepts; Chapter 11 Medications Used to Manage Lupus Erythematosus 327 $aChapter 12 Economic Impact and Disability IssuesChapter 13 Prognosis; Chapter 14 Experimental and Innovative Therapies; Glossary; Appendix; Index 330 $aOne million people in the United States suffer from systemic lupus erythematosus (SLE or lupus), a chronic autoimmune disease that is potentially debilitating and sometimes fatal as the immune system attacks the body's cells and tissue, resulting in inflammation and tissue damage. SLE can affect any part of the body, but most often damages the heart, joints, skin, lungs, blood vessels, liver, kidneys and nervous system. The course of the disease is unpredictable, with periods of illness alternating with remission. It can be treated symptomatically, mainly with corticosteroids and immunosuppres 410 0$aOxford American Rheumatology Library 606 $aLupus erythematosus 615 0$aLupus erythematosus. 676 $a616.7/72 700 $aWallace$b Daniel J$g(Daniel Jeffrey),$f1949-$01592839 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910822235003321 996 $aLupus$93956446 997 $aUNINA